By [ad_1]
BioNTech and partner Pfizer Inc. are counting on an omicron-adapted vaccine to reinvigorate sales for the rest of the year. The first doses of a shot tailored for both the original coronavirus and the fast-spreading omicron BA.4/5 variant should be ready in October, in time for fall booster campaigns, BioNTech said. The companies will begin a clinical trial this month and manufacturing has already started.
[ad_2]
Source link
What is your reaction?
Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0
